Myriad respects your privacy and we never sell or distribute your information to third parties

New Data Shared at AACR-IASLC

New Data Shared at AACR-IASLC

As part of Myriad’s ongoing commitment to advance the science of lung cancer care, we shared exciting new data at this year’s AACR-IASLC International Joint Conference in San Diego. Here is a quick recap of the poster presentation targeted at improving patient outcomes in early stage lung cancer.



Recurrence and lung cancer mortality in resected, early stage non-small cell lung cancer (NSCLC) are likely due to the presence of micro-metastatic disease not detected during surgery or the pre-surgical assessment. The aim of this study was to validate cell cycle progression gene expression (CCP Score) and the molecular Prognostic Score as predictors of 5-year distant recurrence-free survival in a cohort of surgically treated lung adenocarcinomas without adjuvant treatment.

Content Divider


  • The CCP score and the molecular prognostic score are independent prognostic markers of 5-year distant recurrence in patients with early stage lung adenocarcinoma treated with surgery, independent of age, tumor size and pleural invasion.
  • The prediction of risk of distant recurrence in resected lung adenocarcinoma patients can be improved over that obtained by the current standard of pathological stage by incorporating tumor expression of proliferation markers (CCP score).
  • Improved risk stratification can help identify patients in need of additional treatment and prioritize patients for trials of emerging new therapies.

Click here to view the full version of this poster

For more information on how myPlan Lung Cancer incorporates tumor aggressiveness and pathological stage to provide an accurate and objective measure of patient mortality risk, please visit


Myriad myRisk App

Find clinical information associated with Myriad’s myRisk cancer test.


Myriad Promise

Myriad promises to provide affordable access to testing.

Hereditary Cancer Quiz

Identify appropriate patients for hereditary cancer testing before or during your patient’s appointment.


Patient Education Videos

Guide your discussions with patients on hereditary cancer syndromes.

Search by Product

myChoice HRD myPath Melanoma myRisk Prolaris

Search by Cancer

Breast Colorectal Endometrial Lung Ovarian Prostate

Search by Specialty

Genetic Counselor Obstetrics and Gynecology Oncologist Primary Care Radiology


Myriad, the Myriad logo, MyriadPro, the MyriadPro logo, Myriad myRisk Hereditary Cancer, the Myriad myRisk Hereditary Cancer logo, Myriad myPath Melanoma, the Myriad myPath Melanoma logo, Myriad myPlan Lung Cancer, the Myriad myPlan Lung Cancer logo, BRACAnalysis, the BRACAnalysis logo, COLARIS, the COLARIS logo, COLARIS AP, the COLARIS AP logo, MELARIS, the MELARIS logo, PANEXIA, the PANEXIA logo, Prolaris, the Prolaris logo, ResultsNow, the ResultsNow logo, Myriad Promise, and the Myriad Promise logo are either trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and other jurisdictions.